The phenomenon of in vitro activation of the classical complement pathway at low temperatures (4-21°C) is known as cold activation, and has been suggestedto be associated with non-A, non-B hepatitis. We re-examined the association by using newly developed markers of hepatitis C virus (HCY) infection. Twenty-one cases randomly selected from those fulfilling the screening criteria of complement cold activation all showed evidence of HCY infection. More than half of 55 HCY antibody-positive cases selected randomly from our laboratory samples showed a tendency towards cold activation, whereas none of the HCY antibody-negative sera showed cold activation. All the HCY antibody-positive cases were negative in cold activation when CH50 was assayed with plasma. These results, taken together, indicate that cold activation of the complement system is strongly associated with HCY infection.
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The complement system is measured routinely to study the pathophysiology of various diseases. Haemolytic activity (CH50) and complement proteins, especiallyC3 and C4, are measured most often. When blood or serum are kept at low temperature until analysis, the classical complement pathway is activated in vitro in some patients.l' In these patients, the serum CH50 levelis low although the CH50 level in the plasma is within the normal range. When serum is kept at 37°C throughout the process of blood clotting, serum separation and storage until analysis, activities of CH50, C3 and C4 in serum samples are the same as in corresponding plasma samples.i If serum from patients showing the effect is added to normal serum, the C4 activity of the mixture markedly decreases at 4DC but not at 37 DC. 2 The low serum CH50 level in these patients is due to the in vitro activation of the classical complement pathway at low temperature (4°C-21 0C),2 which has been termed cold activation of the complement system in serum.s Correspondence: Dr Akira Shimizu.
The activity of C4 in this type of serum is markedly decreased but the concentration of C4 protein measured by immunoassay is not, because the inactive fragments generated from the intact C4 during cold activation in vitro remain in the serum and react with the anti-C4 antibody.'
Cold activation of the complement classical pathway has been suggested to be triggered by cryoglobulin-like substances;' Previous observations by Inai et al,' indicated the frequent incidence of cold activation among patients with liver diseases. Of their 60 patients with chronic liver diseases, eight showed a very low level of serum CH50 but a normal level of plasma CH50. All eight cases were hepatitis B virus (HBY) surface antigen-negative. Their study was performed before sensitive methods of detecting hepatitis C virus (HCY) infection were available.v' Recently, type II and III cryoglobulins have been found very frequently in sera with concomitant HCY infection.JtP In this study, we re-examined the association of complement cold activation and liver diseases using HCY infection markers.
SUBJECTS AND METHODS

Subjects
We screened all specimens sent to our clinical laboratory for complement assay during a 6-month period. These sera were checked for the level of CH50 and the C4 and C3 concentrations. For screening, the blood samples were kept at room temperature for 1 to 2 h until analysis of CH50. In general, the CH50 level and the C4 protein concentration are correlated. However, sera in which the complement system is activated in vitro tended to deviate from this correlation and showed a rather low CH50 level compared to the C4 concentration ( Fig. 1 ). We set arbitrary criteria for screening of cold activation, that is, CH50< 15 Ulml (normal range 32-48 UlmL) and C4 protein> 10mg/dL. For specimens fulfilling these criteria, the plasma CH50 level was also measured to eliminate those with low levels of complement in vivo. All of the plasma samples tested showed a normal level of CH50. To study the incidence of cold activation in routine specimens, we counted the exact number of samples and patients for 3 months. During this period, 2184 samples from 1204 patients were examined.
We measured CH50 after storage of blood at room temperature for 1 to 2 h and also after storage of the serum at 4°C overnight for the following samples; 68 healthy control cases negative for HCV antibody (second generation method), 55 HCV antibody-positive cases selected randomly from our laboratory samples, and 20 HCV antibody-negative cases also selected randomly.
Twenty-one cases selected randomly from samples satisfying our criteria of screening cold activation were examined for HCV and HBV infection markers, aspartate aminotransferase (AST), alanine aminotransferase (AL T) and rheumatoid factor.
Methods
Complement haemolytic activity and C3 and C4 concentrations: CH50 was determined by a modification of the method of Mayer et al. , 13 which was adapted to a one-point measurement'" using sensitized sheep red blood cells (Denka Laboratory, Tokyo, Japan) and an automated analyser (Cobas Mira Plus, Japan Roche Co. Ltd, Tokyo, Japan). Rheumatoid factor, C3 and C4 were measured by nephelometric assays using an automated analyser (BNA, Hoechst Japan Co. Ltd, Tokyo, Japan).
Ann Clin Biochem 1993: 30 HCV antibody was assayed using a firstgeneration radioimmunoassay kit (HCV Ab IRMA test; Ortho Diagnostic systems, Raritan, NJ, USA; recombinant antigen, Cl00-3) and a second-generation enzyme-linked immunosorbent assay kit (HCV EIA II; Abbott Diagnostics, Abbott Park, IL, USA; recombinant antigen, C100-3, pHCV-34, pHCV-31). HCV ribonucleic acid (RNA) and HBV S antibody and S antigen were assayed as previously described.Pr!?
RESULTS
Incidence of cold activation in our laboratory samples Twelve of 1204 patients on whom 2184 complement assays were performed satisfied the screening criteria for cold activation.
Incidence of positive cases of hepatitis infection markers in specimens showing cold activation
Twenty-one cases showing cold activation were selected randomly and examined for hepatitis markers. As shown in Table I , all 21 cases were HCV antibody positive by the second generation assay, all nine cases tested were HCV antibody (first generation) positive, and 15 of 21 cases were HCV RNA positive by polymerase chain reaction (PCR). All cases examined were HBV S antigen negative, and 4 of 15 cases tested were HBV S antibody positive. Fifteen of 21 cases showed abnormal transaminase levels, and nine of 19 cases tested were rheumatoid factor positive.
Incidence of cold activation in HCV antibody-positive sera In Figs 1 and 2, CH50 levels are plotted against respective C4 concentrations for HCV antibody (second generation) negative and positive cases. For specimens kept at room temperature, six of 55 randomly selected HCV antibody-positive cases showed cold activation by the criteria described above (Fig. 1a) . After keeping the serum at 4°C overnight, 14 of 55 cases clearly showed cold activation (Fig. 1b) . In contrast, none of the 20 HCV antibody-negative cases chosen from our laboratory samples and none of the 68 HCV antibody-negative healthy controls showed cold activation in either condition. Further, none of the 28 HCV antibody-positive cases tested showed cold activation when CH50 was assayed with EDTA-plasma (Fig. 2) .
The plots of normal controls in Fig la and All cases with complement cold activation showed evidence of HCY infection. More than half of the HCY antibody-positive cases showed a tendency towards cold activation. All HCY antibodynegative controls showed no cold activation. The general incidence of HCY antibody-positive cases in the area of our hospital is 1'15070. 18 We conclude that the cold activation of the complement system is strongly associated with HCY infection.
Hepatitis C and B virus markers and complement levels in patients showing complement cold activation
Recently, type II and III cryoglobulins have been reported to be associated with concomitant HCY infection,S-12 and the complement system appears to be activated by cryoglobulin-like substances. 1. 2 We undertook a preliminary study of the sera from nine cases showing cold activation for cryoglobulin formation. The sera were kept at 4°C for a week and three cases showed detectable precipitates. Cold activation and formation of cryoglobulin type II or III may be related phenomena. Type II and III cryoglobulins consist of IgG and IgM rheumatoid factors. IgM is monoclonal in type II and polyclonal in type III. The association of cold activation with HCY infection found in the present study is stronger than that of the mixed type cryoglobulinaemia reported previously. S-12 Both phenomena at low temperature in vitro may be generated by a similar but not necessarily identical mechanism. Serum samples reacting to HCY antigen (ClOO-3) at 24°C but not at 37°C have been found in blood donors, and the antibody showed low avidity to ClOO-3 antigen and consisted of an IgG 3 subclass.'? These findings suggest that some epitopes of HCY stimulate synthesis of antibody which reacts with antigen preferentially at lower temperatures, and that the HCY or HCY-antibody complex stimulates synthesis of rheumatoid factor, which also binds to the immune complex more strongly at lower temperatures. It is possible that the antigen (HCY)-antibody complex formed at low temperature activates complement in vitro but does not form cryoprecipitate, and that an HCY antigen-antibody-rheumatoid factor complex induces cold activation and generates DISCUSSION but that many of the HCY antibody-positive cases deviated from this correlation. More than half (24/40) of the antibody-positive cases appear in the area of lower CH50 levels than those expected from their C4levels (Fig. lb) , These low values are generated by cold activation. Ann C/in Biochem 1993: 30 cryoprecipitate. The antibody may belong to IgG J , and this subclass antibody may activate complement more strongly than other subclasses.
